• Support legislation to reform Congressional Budget Office scoring of health care legislation
• Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape
• Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated
• Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
• Support promulgation of TCET final rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening
• Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D
• Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
• Support robust domestic supply chain development and manufacturing ecosystem

Duration: January 1, 2008 to present

General Issues: Budget/Appropriations, Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Medical/Disease Research/Clinical Labs, Copyright/Patent/Trademark, Trade (Domestic & Foreign), Manufacturing, Defense, Banking, Disaster Planning/Emergencies, Small Business, Environmental/Superfund, Veterans, Agriculture, Immigration, Financial Institutions/Investments/Securities, Education, Science/Technology

Spending: about $11,187,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Natl Institute of Standards & Technology (NIST), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Securities & Exchange Commission (SEC)